Qilu Pharmaceutical, a leading pharmaceutical company based in China, has received approval from the National Medical Products Administration (NMPA) for its generic version of Celgene’s pomalidomide, expanding treatment options for multiple myeloma patients in China.
This drug, a derivative of the immunomodulator thalidomide, is recognized for its anti-tumor efficacy. It functions by inhibiting the proliferation of hematopoietic tumor cells and promoting cell apoptosis. It is indicated for multiple myeloma patients who have previously been treated with at least two therapies, including lenalidomide and bortezomib, and have either shown disease progression or completed their last treatment within 60 days.
Notably, the original drug, which received approval in the US and the European Union in February and August 2013, respectively, is yet to be approved in China. However, Qilu Pharmaceutical’s generic version of pomalidomide was the first to gain approval in China in November 2020 and was subsequently included in the National Reimbursement Drug List (NRDL) in late 2021.- Flcube.com
